Image Of 10 mg Package Label (6207)
Donepezil Hydrochloride
Product Images NDC 54868-6207
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 54868-6207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Of 5 mg Package Label (6208)
This is a medication label for Donepezil SKG, distributed by Physicians Total Care. The medication is in tablet form and comes in a bottle with 30 tablets. The bottle has the NDC code HDC 54868-6208-8 and the lot number LB, with an expiration date of 01760. The dosage and strength of the medication are not specified.*
Image Of Chemical Structure (Chemical Structure)
Image Of Figure 1 (Figure01)
The text appears to be a mixture of numerical and short text fragments with some errors. It is not clear what the text is referring to, and therefore, a useful description cannot be generated.*
Image Of Figure 2 (Figure02)
This text represents data from a study on a drug's effect on Alzheimer's disease. The results show the percentage of patients who completed the study and their change in ADAS-cog score. This score measures cognitive abilities related to Alzheimer's disease. The study was double-blind, and patients were given a placebo or one of two doses of the drug. The study lasted for 24 weeks, and the results indicate that patients on the drug had a greater improvement than those on a placebo.*
Image Of Figure 3 (Figure03)
The text is displaying the percentage of patients and their respective levels of improvement or worsening in a certain program or treatment. There is also a frequency distribution chart related to CIBIC phes scores for week 24.*
Image Of Figure 4 (Figure04)
Image Of Figure 5 (Figure05)
This appears to be a table and graph of results from a study testing the effects of different treatments on patients' ADAS-cog scores. The text includes information on the change in scores for each treatment group as well as the cumulative percentage of patients who experienced certain changes from their baseline scores. The percentages of patients who completed the study in each treatment group are also provided.*
Image Of Figure 6 (Figure06)
Image Of Figure 7 (Figure07)
The text appears to be a table and figure caption related to clinical improvement and decline based on patients' SIB scores over a certain period of time. The table displays mean change values while the figure shows the timeline of changes from baseline. There is not enough information to determine the context of the study or the nature of the patients' conditions.*
Image Of Figure 8 (Figure08)
This is a graph showing the cumulative percentage of patients that completed 6 months of double-blind treatment with particular changes from baseline in SIB (Severe Impairment Battery) scores. The graph shows the percentage of patients on the Y-axis and the changes from baseline on the X-axis.*
Image Of Figure 9 (Figure09)
Image Of Figure 10 (Figure10)
This is a graph showing the cumulative percentage of patients completing 6 months of double-blind treatment with particular changes. The scale is from 0 to 100, with the horizontal axis showing the change from baseline. However, the text is not properly recognized as it includes gibberish characters, possibly due to errors.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
